2025年2月5日， 波士顿科学 公布了2024年第四季度及全年业绩。 其中， 电生理业务 第四季度销售额为 6.49亿美元 ，全年销售额为 19亿美元 ，分别同比增 长近 171% 和 138% 。 财报称，在2024年初获得 FDA 批准后，其 FARAPULSE脉冲场消融系统 到2024年底的销售额 超过10亿美元（72.88亿美元） 。 该公司领导层此前曾将 FARAPULSE描述为 波士顿科学公司历史上最具变革性的产品 。自商业推出以来，它推动了电生理学销售额的增长，包括 2024 年第 一季度的同比增长 70%、第二季度的 125% 和第三季度的 177%。 波士顿科学董事长兼CEO Mike Mahoney 说，"2024年是波科历史上表现最佳的年份之一，得益于我们的创新产品组合、FARAPULSE系统的上市，以及跨业 务和地区的临床与商业化突破。我们已奠定强劲增长基础，并将持续变革全球数百万患者的生活。" # 何为FARAPULSE 系统？ 作为 全球被研究和使用最多的PFA （脉冲电场消融） 系统 ，波士顿科学的FARAPULSE 系统迄今已治疗超过7万名患者。 FARAPULSE 系统可通 ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Boston Scientific (BSX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Boston Scientific is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is ...

2025年2月5日， 波士顿科学 公布了 2024年第四季度及全年业绩 ， 第四季度销售额 45.61亿美元（约合332亿人民币） ，同比增长22.4%；全年总营收 167.47亿美元（约合1220亿人民币） ， 同比 增长17.6%。 # 财报亮点 第四季度的净销售额 为45.61亿美元 ，同比增长22.4%（报告）、23.1%（运营）和19.5%（有机）；每股收益（EPS）为0.38美元，同比增长11.8%，调整后 为0.70美元，同比增长27.3%； 毛利率为67.9%，同比下降130个基点；调整后为70.6%，同比增长20个基点；营业利润率为14.8%，同比下降90个基点；调整 后为27.4%，同比增长80个基点。 全年净销售额为167.47亿美元 ，同比增长17.6%（报告）、18.5%（运营）和16.4%（有机）；每股收益（EPS）为1.25美元，同比增长20.0%，调整后为2.51 美元，同比增长100.0%；毛利率为68.6%，同比下降90个基点；调整后为70.3%，同比下降40个基点；营业利润率为15.5%，同比下降100个基点，调整后为 27.0%，同比增长70个基点。 | Q4 & FY ...

Financial Data and Key Metrics Changes - In Q4 2024, operational sales grew 23% and organic sales grew 20%, exceeding the guidance range of 14% to 16% [10] - Full year 2024 operational sales grew 18.5% while organic sales grew 16%, surpassing the guidance of approximately 15% [10] - Q4 adjusted EPS was $0.70, a 26% increase, exceeding the guidance range of $0.64 to $0.66 [11] - Full year adjusted EPS was $2.51, a 22% increase, exceeding the guidance range of $2.40 to $2.47 [11] - Adjusted operating margin for full year 2024 was 27%, an increase of 70 basis points [12] Business Line Data and Key Metrics Changes - Urology grew 8% in Q4 and 9% for the full year, with operational growth of 20% in Q4 [17] - Endoscopy sales grew 8% operationally and 7% organically in Q4, with full year growth of 9% operationally [20] - Cardiology sales grew 32% in Q4 and 25% for the full year, with interventional cardiology therapies growing 10% in Q4 [23] - Electrophysiology sales grew 172% in Q4 and 139% for the full year, driven by FerraPulse [29] Market Data and Key Metrics Changes - U.S. operational growth was 31% in Q4 and 21% for the full year [14] - Asia Pacific grew 12% operationally in Q4 and 16% for the full year, with strong performance in Japan and China [15] - Middle East, Europe, and Africa grew 12% in Q4 and 14% for the full year [14] Company Strategy and Development Direction - The company aims to continue outpacing market growth in 2025, with expectations of organic growth of 14% to 16% [12] - Focus on innovation and execution across global business units, with significant investments in product development [10] - Strategic acquisitions, such as Bolt Medical and Intera Oncology, are expected to enhance the product portfolio [12][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining strong growth momentum despite potential competition in the PFA market [75] - Anticipated challenges in China due to VBP pricing pressures, but still expect mid-teens growth [17] - Management remains focused on driving differentiated results and enhancing the company culture [36] Other Important Information - Free cash flow for Q4 was $1.181 billion, with full year free cash flow of $2.648 billion, achieving 71% conversion [43] - The company has a cash reserve of $414 million and a gross debt leverage ratio of 2.2 times [44] - Guidance for 2025 includes reported revenue growth of 12.5% to 14.5% and organic growth of 10% to 12% [45] Q&A Session Summary Question: Thoughts on PFA and Watchmen growth - Management noted excellent momentum in both FerraPulse and Watchmen, with a slight uptick in Watchmen growth due to reimbursement changes [60] Question: Long-term growth expectations - Management indicated a goal to outgrow market growth rates and maintain double-digit EPS growth despite potential tax rate increases [68] Question: Risks and upside in guidance - Management acknowledged potential competition in the PFA market but emphasized strong momentum across various regions and product lines [75] Question: Margin management and cash flow - Management discussed strategies for operating margin expansion and maintaining a focus on high-quality M&A as a primary use of cash [85] Question: Update on TAVR franchise - Management stated that discussions regarding the U.S. TAVR franchise are ongoing, with strong performance in Europe despite some impacts from U.S. trials [123] Question: Mapping strategy and market share - Management confirmed an open platform strategy for mapping, with a focus on enhancing the OPAL platform while supporting competitive systems [126]

Boston Scientific Corporation (BSX) posted fourth-quarter 2024 adjusted earnings per share (EPS) of 70 cents, up 27.3% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 7.7% and also exceeded the company’s adjusted earnings per share guidance range of 64-66 cents per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The quarter’s adjustments included certain amortization expenses, acquisition/divestitures-related net charges, and restructuring and restructu ...

Boston Scientific (BSX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.69%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $0.58 per share when it actually produced earnings of $0.63, delivering a surprise of 8.62%.Over the last four qua ...

FOR IMMEDIATE RELEASE Boston Scientific announces results for fourth quarter and full year 2024 For the full year 2024, the company generated net sales of $16.747 billion, growing 17.6 percent on a reported basis, 18.5 percent on an operational basis and 16.4 percent on an organic basis. The company reported GAAP net income attributable to Boston Scientific common stockholders of $1.853 billion or $1.25 per share, compared to $1.570 billion or $1.07 per share a year ago, and delivered full year adjusted EPS ...

Core Insights - Boston Scientific Corporation reported net sales of $4.561 billion in Q4 2024, representing a growth of 22.4% on a reported basis, 23.1% operationally, and 19.5% organically compared to the previous year [1][9] - For the full year 2024, the company achieved net sales of $16.747 billion, an increase of 17.6% reported, 18.5% operationally, and 16.4% organically [2][12] - The company’s GAAP net income for Q4 2024 was $566 million or $0.38 per share, up from $504 million or $0.34 per share a year earlier, with adjusted EPS of $0.70 compared to $0.55 [1][9] - The CEO highlighted 2024 as one of the best years in the company's history, driven by an innovative portfolio and significant clinical achievements [3] Financial Performance - Q4 2024 net sales by segment included: MedSurg (12.4% reported), Cardiovascular (28.8% reported), and Urology (19.5% reported) [9][10] - Regional performance in Q4 2024 showed the U.S. with a 30.7% increase, EMEA at 10.8%, APAC at 11.1%, and LACA at 4.6% [9][10] - For the full year 2024, the U.S. contributed $10.210 billion in sales, a 21.2% increase, while EMEA and APAC saw increases of 13.0% and 11.9% respectively [12][12] Recent Developments - The company presented positive clinical trial findings for the WATCHMAN FLX™ device and the FARAPULSE™ system, indicating advancements in treatment efficacy [9][10] - Boston Scientific received FDA approval for new products, including the Vercise™ Cartesia™ leads and AGENT™ Drug-Coated Balloon, enhancing its product offerings [9][10] - The company completed acquisitions of Axonics, Inc. and Cortex, Inc., expanding its capabilities in medical technology [9][10] Guidance - For 2025, Boston Scientific estimates net sales growth of approximately 12.5% to 14.5% on a reported basis and 10% to 12% organically [14][15] - The company projects GAAP EPS for 2025 to be in the range of $1.86 to $1.93, with adjusted EPS expected between $2.80 and $2.87 [14][16]

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.65 per share, indicating an increase of 18.2% compared to the year-ago period. Analysts forecast revenues of $4.4 billion, representing an increase of 18.1% year over year.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Prior to a company's ...